Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Molecular Pharmaceutics

• Publication date

  2011-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp200337hPMID 22014118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug.

  2011cited by this paper
• Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.

  2010cited by this paper
• Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic‐pharmacodynamic study using in vivo microdialysis in rats

  2010cited by this paper
• The use of drug metabolism for prediction of intestinal permeability (dagger).

  2009cited by this paper
• New drug delivery strategies for improved Parkinson's disease therapy

  2009cited by this paper
• Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.

  2009cited by this paper
• Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease.

  2009cited by this paper
• New drug delivery strategies for improved Parkinson's disease therapy.

  2009cited by this paper
• Antiparkinson Prodrugs

  2008cited by this paper
• Levodopa for the treatment of Parkinson's disease.

  2008cited by this paper
• In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.

  2008cited by this paper
• Intravenous levodopa administration in humans based on a two-compartment kinetic model.

  2007cited by this paper
• High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated rats

  2007cited by this paper
• In vitro - in vivo correlation: from theory to applications.

  2006cited by this paper
• L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties.

  2006cited by this paper
• Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs.

  2006cited by this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  2006cited by this paper
• Apomorphine in dopaminergic therapy.

  2006cited by this paper
• How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment.

  2005cited by this paper
• Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC.

  2005cited by this paper
• Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.

  2005cited by this paper
• The tribulations and successes on the road from DSC to TMDSC in the 20th century the prospects for the 21st century

  2004cited by this paper
• In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis.

  2004cited by this paper
• Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes

  2004cited by this paper
• Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress.

  2004cited by this paper
• Long term motor complications of levodopa: clinical features, mechanisms, and management strategies

  2004cited by this paper
• Alpha lipoic acid changes iron uptake and storage in lens epithelial cells.

  2003cited by this paper
• Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling.

  2003cited by this paper
• PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release.

  2002cited by this paper
• Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres.

  2001cited by this paper
• Manganese increases L‐DOPA auto‐oxidation in the striatum of the freely moving rat: potential implications to L‐DOPA long‐term therapy of Parkinson's disease

  2000cited by this paper
• Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid

  1997cited by this paper
• Biodegradation and biocompatibility of PLA and PLGA microspheres.

  1997cited by this paper
• Neuroprotection by the metabolic antioxidant alpha-lipoic acid.

  1997cited by this paper
• Levodopa ethylester : A novel rescue therapy for response fluctuations in parkinson's disease

  1996cited by this paper
• Elucidation of antioxidant activity of alpha-lipoic acid toward hydroxyl radical.

  1995cited by this paper
• Elucidation of antioxidant activity of α-lipoic acid toward hydroxyl radical

  1995cited by this paper
• Poly (glycolic acid-co-dl-lactic acid): diffusion or degradation controlled drug delivery?

  1992cited by this paper
• Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats.

  1990cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

  1975cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper
• Letters to the Editor: Linearization of dissolution rate curves by the Weibull distribution

  1972cited by this paper
• KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG.

  1964cited by this paper

• Synthesis of chitosan-graphene oxide thermosensitive in situ hydrogel for nasal delivery of rasagiline mesylate: In-vitro-ex vivo characterization

  2024cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• Nanomedicine and drug delivery: A comprehensive review of applications and challenges

  2024cites this paper
• From self-Assembly to healing: Engineering ultra-Small peptides into supramolecular hydrogels for controlled drug release.

  2024cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

  2024cites this paper
• The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems

  2023cites this paper
• Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment.

  2023cites this paper
• Polymer supported electrospun nanofibers with supramolecular materials for biological applications – a review

  2022cites this paper
• A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles.

  2022cites this paper
• Kinetics of Controlled Cure System Triggered by Release of Encapsulated Catalyst

  2021cites this paper
• Redox nanoparticles

  2020cites this paper
• A GSH-Responsive Nanoprodrug System Based on Self-Assembly of Lactose Modified Camptothecin for Targeted Drug Delivery and Combination Chemotherapy

  2020cites this paper
• Therapeutic Nanomaterials for Neurological Diseases and Cancer Therapy

  2020cites this paper
• Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice.

  2019cites this paper
• Mathematical Modeling of Release Kinetics from Supramolecular Drug Delivery Systems

  2019cites this paper
• Intra-articular Drug Delivery Systems for the Treatment of Osteoarthritis

  2019cites this paper
• Nanodelivery of therapeutic agents in Parkinson's disease.

  2019cites this paper
• Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

  2019cites this paper
• Apollonian emulsions - coalescence in high internal-phase-ratio emulsions

  2019cites this paper
• A thermo‐responsive and self‐healing liposome‐in‐hydrogel system as an antitubercular drug carrier for localized bone tuberculosis therapy

  2019cites this paper
• Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.

  2018cites this paper
• Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment

  2017cites this paper
• L-dopa co-drugs in nanostructured lipid carriers: A comparative study.

  2017cites this paper
• Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges.

  2016cites this paper
• Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease

  2016cites this paper
• Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.

  2016cites this paper
• Design of Macromolecular Anti-cancer Drug Delivery Systems using Molecular Dynamics Simulation

  2015cites this paper
• Release and pharmacokinetics of near-infrared labeled albumin from monodisperse poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcapsular renal injection.

  2015cites this paper
• Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.

  2015cites this paper
• Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders

  2015cites this paper
• Drug delivery system based on cyclodextrin-naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibers.

  2014cites this paper
• Determination of degradation behavior of biodegradable polymers for pharmaceutical devices What are the physical properties that influence degradation and how is it predictable / measurable ?

  2014cites this paper
• In situ forming hydrogels for intra-articular delivery of celecoxib: from polymer design to in vivo studies

  2014cites this paper
• In-vitro Modeling of the Release Kinetics of Micron and Nano-Sized Polymer Drug Carriers

  2014cites this paper
• Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides

  2014cites this paper
• Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels.

  2014cites this paper
• Prolonged analgesic effect of amitriptyline base on thermal hyperalgesia in an animal model of neuropathic pain.

  2013cites this paper
• Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.

  2013cites this paper
• Nanoengineered drug-releasing Ti wires as an alternative for local delivery of chemotherapeutics in the brain

  2012cites this paper
• Role of peripheral and brain-derived dopamine (DA) in immune regulation

  2012cites this paper